RonMathijssen
RonMathijssenstudiedmedicineattheErasmusUniversityRotterdamforwhichhereceivedhisMDdegreein2000.Twoyearslaterhedefendedhisthesis(cumlaude)entitled:‘Irinotecan:fromClinicalPharmacokineticstoPharmacogenetics’.Subsequently,hebecameInternist,MedicalOncologist,andClinicalPharmacologist.Heiscloselycollaboratingwithnationalandinternationalgroups,supervisesseveralPhDstudents,andpublishedover120peerreviewedpapers.Inaddition,heteachesstudents,reviewspapersformanyjournals,andisamemberoftheDutchCancerSocietyscientificcounsel.Finally,heischairoftheDutchPharmacologyOncologyGroup;anationalcollaborationtoindividualizethedoseofanti-cancerdrugs.Since2013,heisaprofessorinIndividualizedOncologicalPharmacotherapyattheDepartmentofMedicalOncology,headingthedivisionofTranslationalPharmacology.Hismainresearchisfocusedon‘tailoredtherapy’ofsystemicanti-canceragentsliketaxanes,tamoxifen,irinotecan,tyrosinekinaseinhibitors,andphaseIdrugs.